DNA甲基化对HbF出生后沉默至关重要
本文综述近期证据,确认HBG基因启动子DNA甲基化是出生后沉默胎儿血红蛋白(HbF)表达的关键机制,并支持一个模型:HBG启动子CpG位点甲基化及抑制性转录因子招募MBD2-NuRD染色质重塑复合物以执行沉默。这些发现对β-珠蛋白疾病治疗有启示。
要点
- HBG启动子甲基化是出生后沉默HbF的关键机制。
- 甲基化CpG与抑制性转录因子协同招募MBD2-NuRD复合物。
- 该机制对镰状细胞病和β-地中海贫血治疗有潜在意义。
核心结论
- HBG基因启动子DNA甲基化是出生后沉默HbF表达所必需的。
主要发现
- HBG启动子CpG位点甲基化与抑制性转录因子共同招募MBD2-NuRD染色质重塑复合物。
- 该复合物执行并维持HbF沉默。
临床怎么用
- 针对HBG启动子甲基化或MBD2-NuRD复合物可能为提升HbF治疗β-珠蛋白疾病提供策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sufficient levels of fetal hemoglobin (HbF) can ameliorate the pathophysiologic basis of sickle cell disease and β-thalassemia postnatally. DNA methylation has long been posited to mediate silencing of HbF expression, but this has been controversial. Recent publications provide definitive evidence for the critical role of HBG gene promoter methylation in silencing and insight into the mechanisms involved. The data support a model in which methylation of CpG sites in the HBG promoters and repressive transcription factors recruit the MBD2-NuRD chromatin remodeling complex, which enforces silencing. These findings have implications for the treatment of β-globin disorders.
引用
- Ginder GD, Shang S, Williams DC, et al. DNA methylation matters: methylation of the γ-globin (HBG) gene promoters is required for postnatal silencing of HbF. Blood. 2026. PMID: 41587075. doi:10.1182/blood.2025031153
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。